Provided by Tiger Trade Technology Pte. Ltd.

Benitec Biopharma

8.98
-0.6000-6.26%
Post-market: 8.980.00000.00%16:10 EDT
Volume:135.14K
Turnover:1.23M
Market Cap:313.25M
PE:-9.18
High:9.88
Open:9.71
Low:8.92
Close:9.58
52wk High:16.76
52wk Low:8.92
Shares:34.88M
Float Shares:18.45M
Volume Ratio:1.09
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9783
EPS(LYR):-0.9800
ROE:-33.21%
ROA:-22.67%
PB:1.77
PE(LYR):-9.16

Loading ...

Benitec Biopharma Appoints Ernst & Young as Independent Auditor for Fy2027

Reuters
·
Oct 01

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Benitec Biopharma (BNTC)

TIPRANKS
·
Sep 28

Benitec Biopharma Switches Auditor to Ernst & Young from Baker Tilly

Reuters
·
Sep 25

BNTC: BB-301 Clinical Progress and Strong Cash Position Drive Ritu Baral’s Buy Rating

TIPRANKS
·
Sep 16

Benitec Biopharma price target raised to $17 from $16 at Wedbush

TIPRANKS
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), CVS Health (CVS) and BioNTech SE (BNTX)

TIPRANKS
·
Sep 15

Wedbush Lifts Price Target on Benitec Biopharma to $17 From $16, Keeps Outperform Rating

MT Newswires Live
·
Sep 15

Benitec Biopharma Files $200 Million Shelf Registration

MT Newswires Live
·
Sep 15

Benitec Biopharma files $200M mixed securities shelf

TIPRANKS
·
Sep 15

Benitec Biopharma - May Offer Securities up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Sep 15

Benitec Biopharma Q4 EPS $(0.26), Inline

Benzinga Earnings
·
Sep 15

Benitec Biopharma Publishes Fy2026 Annual Report

Reuters
·
Sep 15

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

THOMSON REUTERS
·
Sep 15

Benitec Biopharma Initiated at Outperform by Wedbush

Dow Jones
·
Jul 28

Benitec Biopharma Inc : Wedbush Initiates Coverage with Outperform Rating; Target Price $16

THOMSON REUTERS
·
Jul 28

Wedbush Initiates Benitec Biopharma at Outperform With $16 Price Target

MT Newswires Live
·
Jul 28

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 07

Novartis Receives European Commission Approval for Itvisma® for Spinal Muscular Atrophy (SMA)

Reuters
·
Jul 02

Benitec Biopharma downgraded to Neutral from Buy at Guggenheim

TIPRANKS
·
Jun 10

Benitec Biopharma Announces Board Changes and New Director

TIPRANKS
·
May 30